Journal
ARCHIVES OF DERMATOLOGICAL RESEARCH
Volume 302, Issue 7, Pages 531-538Publisher
SPRINGER
DOI: 10.1007/s00403-010-1061-4
Keywords
Psoriasis; Multiple sclerosis; Dimethylfumarate; Monomethylfumarate; Fumaric acid esters; Anti-inflammatory drugs
Categories
Funding
- Fumapharm
- Biogen Idec
Ask authors/readers for more resources
The aim of this study was to evaluate pharmacokinetic parameters of fumaric acid esters (FAE) in psoriasis patients for the first time. For this prupose new HPLC assays were developed. Additionally, physicochemical parameters of FAE were determined, allowing a better interpretation of the in vivo data. In vivo, monomethylfumarate (MMF) and monoethylfumarate (MEF) were detected after t (lag) = 120 min. T (max) and c (max) of MMF were 210 min and 11.2 mu M, respectively, 210 min and 5.2 mu M for MEF. The half-life of MMF was 38.7 min, and 25.4 min of MEF. The AUC(0-a) of MMF was 172 min mu g ml(-1) and 63.6 min mu g ml(-1) of MEF. Data display median of three subjects. No plasma levels of dimethylfumarate (DMF) or fumaric acid (FA) were detected. The evaluation of physicochemical parameters of FAE showed that only DMF fulfils the criteria of Lipinski's rule of five. The pKa of MMF was determined as 3.63. The data of this study provide evidence that DMF is most likely absorbed out of the duodenum into the presystemic circulation and is not completely hydrolysed to MMF before uptake as assumed by others.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available